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Screening of DUB activity and specificity
by MALDI-TOF mass spectrometry
Maria Stella Ritorto1, Richard Ewan1,*, Ana B. Perez-Oliva1,*, Axel Knebel1, Sara J. Buhrlage2,3,
Melanie Wightman1, Sharon M. Kelly4, Nicola T. Wood1, Satpal Virdee1, Nathanael S. Gray2,3,
Nicholas A. Morrice5, Dario R. Alessi1 & Matthias Trost1
Deubiquitylases (DUBs) are key regulators of the ubiquitin system which cleave ubiquitin
moieties from proteins and polyubiquitin chains. Several DUBs have been implicated in
various diseases and are attractive drug targets. We have developed a sensitive and
fast assay to quantify in vitro DUB enzyme activity using matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry. Unlike other current assays, this
method uses unmodified substrates, such as diubiquitin topoisomers. By analysing 42 human
DUBs against all diubiquitin topoisomers we provide an extensive characterization of DUB
activity and specificity. Our results confirm the high specificity of many members of the OTU
and JAB/MPN/Mov34 metalloenzyme DUB families and highlight that all USPs tested display
low linkage selectivity. We also demonstrate that this assay can be deployed to assess
the potency and specificity of DUB inhibitors by profiling 11 compounds against a panel
of 32 DUBs.
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P
osttranslational modifications with ubiquitin control almost
every process in cells. Ubiquitylation is facilitated by
ubiquitin-activating (E1s), ubiquitin-conjugating (E2s)
and ubiquitin ligase enzymes (E3s). Ubiquitin can be attached
to substrate proteins as a single moiety or in the form of
polymeric chains in which successive ubiquitin molecules are
connected through specific isopeptide bonds. These bonds can be
formed on any of the eight primary amines of the ubiquitin
molecule (linear/amino (N) terminus/M1, K6, K11, K27, K29,
K33, K48 and K63) and thus can achieve a remarkable
complexity, termed the ubiquitin code1, in which the different
chain topologies serve distinct signalling functions2.
Ubiquitylation is reversible by specific cleavage through
deubiquitylases (DUBs), of which about 90 have been identified
in the human genome3. DUBs have been divided into five
subclasses: ubiquitin carboxy (C)-terminal hydrolases (UCHs),
ubiquitin-specific proteases (USPs), Machado–Joseph disease
protein domain proteases (MJDs), ovarian tumour proteases
(OTUs) and JAB/MPN/Mov34 metalloenzyme (JAMM) domain
proteases3–5. UCHs, USPs, OTUs and MJDs function as papain-
like cysteine proteases, whereas JAMMs are zinc-dependent
metalloproteases6. A sixth family of DUBs, monocyte chemotactic
protein induced proteases has recently been proposed, but little is
known about this family so far4,6.
DUBs have an essential role in ubiquitin homeostasis by
catalysing the editing and disassembly of polyubiquitin chains4.
Furthermore, DUBs also perform signalling functions by the
regulatory deubiquitylation of target proteins3 controlling
proteasome-dependent protein degradation7, endocytosis8, DNA
repair9 and kinase activation10,11. Not surprisingly, DUBs have
been implicated in a number of diseases such as cancer12–17,
inflammation10,18, neurodegeneration/Parkinson’s disease19–21
and, due to their potentially drugable active sites, are
considered attractive drug targets22.
Several chemical probes, such as Ub-vinyl methylester, Ub-
vinyl sulphone23, branched and ubiquitin isopeptide activity-
based probes24 or diubiquitin activity probes25 have been
developed to explore the catalytic properties of DUBs. To
screen for DUB inhibitors, current methods make use of non-
physiological substrates including linear fusion of ubiquitin to a
reporter protein such as phospholipase 2 or yellow fluorescent
protein in a Fluorescent Resonance Energy Transfer assay
format26,27. Moreover, fusions of fluorogenic reporters such as
Rhodamine110 (ref. 28) or 7-amino-4-methylcoumarin29 to the
C-terminal glycine of ubiquitin are also widely deployed.
However, these substrates are not suitable for assessing the
linkage specificity of DUBs. Furthermore, as these are artificial
substrates that do not contain physiological isopeptide bonds,
screening assays using these substrates could potentially identify
compounds that might not inhibit the deubiquitylation of
physiological substrates. To circumvent these issues it is
possible to undertake DUB assays with more physiologically
related diubiquitin molecules30. However these assays are
currently performed using low-throughput SDS–PAGE
methodology and require relatively large amounts of enzymes
(0.01–1mg per assay) and substrates (typically up to 4 mg of
substrate per assay)31.
Matrix-assisted laser desorption/ionization (MALDI) time-of-
flight (TOF) mass spectrometry (MS)32,33 has in the past been
successfully applied to quantify low molecular weight products of
enzymes34 or amyloid-beta peptides produced by gamma-
secretase35. Here, we present a novel screening method to assay
DUB activity and specificity using unmodified diubiquitin isomer
substrates. We employ quantitative MALDI-TOF MS using 15N-
labelled ubiquitin and achieve high sensitivity, reproducibility and
robustness. We analyse the specificity of 42 human DUBs and
characterize the potency and selectivity of 11 DUB inhibitors
against a panel of 32 DUBs. Our data represent an important
resource for the scientific community and establish the
applicability of the MALDI-TOF DUB assay in DUB inhibitor
screening and selectivity assessment.
Results
MALDI-TOF DUB assay to assess DUB activity and specificity.
We have developed a fast and sensitive assay to analyse in vitro
activity and specificity of DUBs by MALDI-TOF mass spectro-
metry, termed the MALDI-TOF DUB assay. In this assay, we
quantitate the amount of monoubiquitin generated by the in vitro
cleavage of specific diubiquitin topoisomers by DUBs (Fig. 1a).
The DUB reaction consists of recombinant DUB (0.1–1,000 ng),
diubiquitin (typically 125 ng, or 7,300 fmol) in 40mM Tris–HCl
pH 7.5, 5mM dithiothreitol (DTT) and bovine serum albumin
(BSA) carrier (0.25 mg) in a total volume of 5ml. Reactions are
undertaken for 1 h at 30 C and terminated by addition of 1ml of
10% (v/v) trifluoroacetic acid. Aliquots (2 ml) of each sample are
spiked with 2ml (1,000 fmol) of 15N-labelled ubiquitin (average
mass 8,666.55Da), whose concentration was established by amino
acid analysis, to serve as an internal standard for ubiquitin
quantitation. A further 2 ml of 15.2mgml 1 2,5-dihydrox-
yacetophenone (DHAP) matrix and 2ml of 2% (v/v) tri-
fluoroacetic acid are added and 0.5 ml of the resultant mixture is
then spotted onto a 1,536 microtiter plate MALDI anchor target.
The samples are analysed by high mass accuracy MALDI-TOF
MS in reflector positive ion mode on an UltrafleXtreme (Bruker
Daltonics) mass spectrometer.
The high resolution and mass accuracy of this MALDI-TOF
mass spectrometer enabled baseline-resolution of isotopic
patterns of ubiquitin and thus reliable quantification of the
area of the ubiquitin peak. Moreover, it permitted clear
separation of the doubly charged diubiquitin molecule (m/z
8,556.64) and the singly charged monoubiquitin (m/z 8,565.76;
Fig. 1b; Supplementary Fig. 1). Next, we tested the linearity of
our assay by analysing standard curves over the ubiquitin
concentration range of 10–10,000 nM (2–2,000 fmol on target)
in the presence of 250 nM 15N-Ubiquitin (42 fmol on the target)
and 874 nM diubiquitin (15 ng ml 1; 146 fmol on the target) in
three separately performed experiments on different days.
Addition of 15N-ubiquitin and/or diubiquitin isomers, did not
affect sensitivity with which ubiquitin could be detected and
quantified (Supplementary Fig. 2). Average correlation coeffi-
cient (r2) for the three curves was not less than 0.99 (Fig. 1c)
showing high linearity over a range of more than 500
(Supplementary Table 1). The mean intraday precision and
interday accuracy for ubiquitin/15N-ubiquitin were 8% and 10%,
respectively, demonstrating the suitability of the assay as a
screening tool. The lower limit of quantification, defined as the
lowest concentration that could be measured with a precision
and accuracy better than 20%, was 10 nM (2 fmol on target;
Fig. 1b) allowing for significantly reduced enzyme and substrate
amounts compared with previously used low-throughput
methods that typically employed up to 4 mg of diubiquitin
(234,000 fmol) per assay.
Determining DUB specificity. Utilizing the MALDI-TOF DUB
assay, we systematically assessed the specificities of 42 recombi-
nant human DUBs (Table 1) against all possible ubiquitin chain
linkages. This represents almost 50% of the DUBs encoded in the
human genome. For this, we determined the DUB activity at five
different enzyme concentrations (from 0.02 to 200 ng ml 1)
against M1/linear, K6, K11, K27, K29, K33, K48 and K63-linked
diubiquitin isomers, all at a final concentration of 1.46 mM in the
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assay. Altogether we performed more than 5,520 enzymatic
reactions, providing the largest published resource for DUB
specificity and activity (Fig. 2). The results of this analysis high-
lighted a striking linkage specificity for five human DUBs
(OTULIN—M1/linear, OTUB1—K48, AMSH, AMSH-LP and
BRCC3—K63), which cleaved only one diubiquitin substrate even
at very high concentrations of enzymes (Fig. 2, group 1), which is
consistent with previous data analysing these enzymes36–38
(Supplementary Table 2). Group 2 consisted of three DUBs that
were highly specific to one linkage at only low concentrations
(Cezanne-K11, OTUD1-K63 and A20-K48) and four DUBs
(TRABID-K29/K33, VCPIPcat-K11/K48, OTUB2- and
phosphorylated OTUD5-K48/K63) that displayed moderate
selectivity hydrolysing two ubiquitin linkages at low
concentrations but were less selective at high concentrations
(Fig. 2, group 2). Twenty DUBs, including all the active USP
family members tested displayed little selectivity (Fig. 2, group 3),
agreeing with previously reported findings39. Four DUBs showed
only very low activity (OTUD6A, OTU1, JOSD2 and ATXN3L)
and six DUBs including OTU6B, JOSD1, and all the ubiquitin
C-terminal hydrolases (UCH) were inactive in our assay (Fig. 2,
group 4; Supplementary Fig. 3).
In parallel, we also performed DUB fluorogenic Ubiquitin-
Rhodamine110-Glycine activity assays (Table 1) which are
frequently used in the field28,40,41. We calculated the specific
activity of each DUB in this assay and grouped these into four
categories (very low, low, moderate and high activity).
Interestingly, when we compared the MALDI-TOF DUB assay
data with fluorescent assay data (Table 1) we found 10 enzymes
(USP9x, USP27x, USP36, CYLD, Otulin, OTUB1, OTUB2,
AMSH, AMSH-LP and BRCC3) that were active only in the
MALDI-TOF DUB assay. Four enzymes (USP10, USP28, A20 and
VCPIP) displaying low activity in the fluorescence assay were
significantly more active in the MALDI-TOF DUB assay. The
majority (18 out of 42) of DUBs tested was active in the MALDI-
TOF DUB assay and displayed moderate or high activity in the
fluorescence assay. In contrast, seven DUBs including all members
of the UCH family as well as OTUD6A, JOSD1 and JOSD2 were
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Figure 1 | The MALDI-TOF DUB assay. (a) Workflow of the MALDI-TOF DUB assay. Each of the 42 DUBs was incubated with all eight diubiquitin isomers
individually (M1, K6, K11, K27, K29, K33, K48 and K63) for 60min at 30 C. The reaction was stopped with 2% TFA and mixed 1:1 with 0.5 mM 15N-ubiquitin
which serves as an internal standard. Subsequently, the analyte is mixed with 2,5 DHAP matrix and spotted onto a 1,536 AnchorChip MALDI target
(Bruker Daltonics). Data analysis is performed using FlexAnalysis (Bruker Daltonics). (b) The MALDI-TOF DUB assay shows high sensitivity. Zoomed area
(8,520–8,720 m/z) of MALDI-TOF MS spectra for ubiquitin (Ubi) and 15N-ubiquitin, in the presence of K11-linked diubiquitin are depicted. The limit of
detection was determined as 2 fmol of ubiquitin on the target (in the presence of 42 fmol of 15N-ubiquitin and 146 fmol of K11-linked diubiquitin). Presence
of the doubly charged diubiquitin (diubiquitin [Mþ 2H]2þ ) does not compromise identification of the singly charged ubiquitin (see also Supplementary
Fig. 2). (c) Linearity and reproducibility of the MALDI-TOF DUB assay. Scatter plot of different concentrations of ubiquitin (10–10,000nM) shows high
linearity over about three orders of magnitude. Interday reproducibility was very high (Supplementary Table 1). Error bars represent s.d. of measurements.
a.u., arbitrary unit; intens., intensity.
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active in the Rhodamine assay but not in the MALDI-TOF DUB
assay. We found that three DUBs tested (OTUD6B, OTU1 and
ATXN3L) displayed very low or no activity, but nevertheless
reacted with an active site-directed probe (C-terminal
propargylated ubiquitin42; Supplementary Fig. 4).
Assessing potency and selectivity of DUB inhibitors. We next
evaluated whether the MALDI-TOF DUB assay had potential to
be deployed to assess potency and selectivity of DUB inhibitors.
To undertake this, we set up a panel of 32 DUBs each assayed
with the preferred diubiquitin isomers displaying the highest
specific activity at the lowest concentration (Supplementary
Fig. 3). As proof of concept, we screened nine previously reported
DUB inhibitors and inhibitor candidates (compound 16 (ref. 43),
L434078, WP1130 (ref. 44), P22077 (ref. 45), Febuxostat (ref. 46),
SJB3-019A (ref. 47), PR-619 (ref. 45), HBX 41,108 (ref. 48),
pimozide (ref. 41)) as well as two E2/E3 ligase inhibitors that have
potential to alkylate Cys residues (NSC 697923 (ref. 49) and BAY
11-7082 (ref. 50)) at two concentrations against a group of 32
highly active DUBs from our assay (Fig. 3; Supplementary Fig. 5;
Supplementary Table 3). In addition, we performed IC50 mea-
surements for the DUBs that were most potently inhibited
(Fig. 4). For these studies, conditions were carefully optimized to
ensure that assays were linear with respect to time
(Supplementary Fig. 6), and the diubiquitin substrate that dis-
played highest activity at the lowest DUB concentration was
selected (Supplementary Fig. 3).
Overall, none of the compounds tested displayed strong
selectivity towards a single DUB and many were unselectively
inhibiting most DUBs on the panel (Fig. 3). For example, PR-619
(ref. 45; Supplementary Fig. 5Q,R), is an ubiquitin/UbL
isopeptidase inhibitor, which has previously been reported to
inhibit a range of cysteine protease DUBs45. Consistent with this,
we found that PR-619 inhibited 27 of the 32 tested DUBs with
Table 1 | DUB enzymes analysed in this study.
DUB family DUB UniProt
accession
number
Tag Domain Host MALDI-TOF DUB Rhodamine-110-Glycine
DUB concentration
for hydrolysis rate
Z20%
Specific activity
(counts per min ng 1)
Activity*
1 Ubiquitin-specific
proteases (USPs)
USP1/UAF1 O94782 His Full length S. frugiperda 2 ng ml 1 92 **
2 USP2b O75604 GST Full length E. coli 2 ng ml 1 133 ***
3 USP4 Q13107 His Full length E. coli 20 ng ml 1 367 ***
4 USP5 P45974 His Full length E. coli 0.2 ng ml 1 59 **
5 USP6 P35125 GST (529–1,406) S. frugiperda 0.02 ngml 1 638 ***
6 USP7 Q93009 His Full length E. coli 0.2 ng ml 1 15 **
7 USP8 P40818 His Full length S. frugiperda 20 ng ml 1 16 **
8 USP9x Q93008 GST (1,553–1,995) E. coli 20 ng ml 1 6 —
9 USP10 Q14694 His Full length S. frugiperda 20 ng ml 1 10 *
10 USP15 Q9Y4E8 GST Full length E. coli 2 ng ml 1 107 ***
11 USP16 Q9Y5T5 His Full length E. coli 2 ng ml 1 323 ***
12 USP20 Q9Y2K6 GST Full length S. frugiperda 2 ng ml 1 405 ***
13 USP21 Q9UK80 His (196–565) E. coli 2 ng ml 1 416 ***
14 USP25 Q9UHP3 GST Full length E. coli 2 ng ml 1 17 **
15 USP27x A6NNY8 DAC Full length S. frugiperda 2 ng ml 1 8 —
16 USP28 Q96RU2 GST Full length E. coli 2 ng ml 1 10 *
17 USP36 Q9P275 GST (81–461) E. coli 200 ng ml 1 6 —
18 CYLD Q9NQC7 His Full length S. frugiperda 2 ng ml 1 4 —
19 UCHs UCHL1 P09936 His Full length E. coli — 218 ***
20 UCHL3 P15374 GST Full length E. coli — 623 ***
21 UCHL5 Q9Y5K5 GST Full length E. coli — 256 ***
22 BAP1 Q92560 GST Full length E. coli — 46 **
23 Ovarian tumour
proteases (OTUs)
OTULIN Q96BN8 GST Full length E. coli 0.02 ngml 1 4 —
24 OTUB1 Q96FW1 GST Full length E. coli 20 ng ml 1 3 —
25 OTUB2 Q96DC9 GST Full length E. coli 2 ng ml 1 5 —
26 OTUD1 Q5VV17 His (270–481) E. coli 0.2 ng ml 1 73 **
27 OTUD3 Q5T2D3 His Full length E. coli 20 ng ml 1 255 ***
28 OTUD5 pS177 Q96G74 GST Full length E. coli 200 ng ml 1 18 **
29 OTUD6A Q7L8S5 His Full length E. coli — 539 ***
30 OTUD6B Q8N6M0 GST Full length E. coli — 9 —
31 OTU1 Q5VVQ6 GST Full length E. coli — 8 —
32 A20 P21580 GST (1–366) E. coli 20 ng ml 1 9 *
33 Cezanne Q6GQQ9 GST Full length E. coli 0.02 ngml 1 466 ***
34 TRABID Q9UGI0 His (245–697) E. coli 20 ng ml 1 16 **
35 vOTU Q6TQR6 His (1–183) E. coli 0.02 ngml 1 670 ***
36 VCPIP1 Q96JH7 His Full length E. coli 2 ng ml 1 13 *
36 VCPIP1 Q96JH7 GST (25–561) E. coli 20 ng ml 1 12 *
37 MJDþ JOSD1 Q15040 His Full length E. coli — 20 **
38 JOSD2 Q8TAC2 His Full length E. coli — 175 ***
39 ATXN3L Q9H3M9 His Full length E. coli — 8 —
40 JAMM/ MPNþ AMSH O95630 GST (256–424) E. coli 20 ng ml 1 5 —
41 AMSH-LP Q96FJ0 GST (265–436) E. coli 0.2 ng ml 1 6 —
42 BRCC3 P46736 His Full length E. coli 2 ng ml 1 8 —
DUB, deubiquitylases; E. coli, Escherichia coli; JAMM, JAB/MPN/Mov34 metalloenzyme; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MJD, Machado–Joseph disease; S.
frugiperda, Spodoptera frugiperda; UCH, ubiquitin carboxy (C)-Terminal hydrolase.
*(—) very low (0–8.9 countsmin 1 ng 1); (*) low (9–14 countsmin 1 ng 1); (**) moderate (15–99 countsmin 1 ng 1); (***) high (100–700 countsmin 1 ng 1) activity by Rhodamine-110-Glycine
assay.
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Figure 2 | Characterizing the linkage specificity of DUBs. Increasing concentrations (0.02–200ng ml 1) of DUBs were incubated in triplicate with
1.46mM of diubiquitin of each linkage type (M1, K6, K11, K29, K33, K48, K63 from Boston Biochem, K27 in-house produced) for 60min at 30 C and
analysed by the MALDI-TOF DUB assay. The amount of monoubiquitin formed by this reaction was determined by MALDI-TOF MS and used to establish
the DUB activity for individual diubiquitin isomers which is shown in a gradient of white (0%) to dark red (100%). The data show that DUBs can be
grouped into enzymes cleaving specifically one linkage type (group 1), few linkage types (group 2), unspecific (group 3) or inactive enzymes (group 4). For
DUB characterization, see Supplementary Figs 3 and 8.
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only members of the OTU and JAMM family being unaffected,
likely because the latter are zinc- metalloproteases and do not
possess a reactive catalytic Cys residue. Furthermore, our data
indicate that SJB3-019A (Supplementary Fig. 5O,P), which has
previously been shown to inhibit USP1 in leukaemic cells47,
inhibits USP8 more strongly (IC50 0.21 mM) than USP1 (IC50
1.69 mM) but in addition also significantly inhibited several other
DUBs tested. Another reported USP1 inhibitor, pimozide41, was
also found to be nonselective, inhibiting many other DUBs with
similar affinity to USP1 (Supplementary Fig. 5E,F).
USP7 is one of the most targeted DUBs as phenotypes
associated with USP7 silencing strongly suggest that small
molecule inhibitors of USP7 may have the potential for antiviral
and anticancer therapies13,51. HBX 41,108, a cyano-
indenopyrazine inhibitor of USP7 that has been shown to
stabilize polyubiquitylated p53 at high concentrations in HEK293
cells48 inhibited 25 of the 32 DUBs tested more than 70% at 5 mM
(Fig. 3). This is consistent with another report suggesting that
HBX 41,108 reacted with additional DUBs52. Only members of
the JAMM family are not affected by HBX 41,108, again likely
because they are zinc-metalloproteases and not cysteine proteases
(Supplementary Fig. 5S,T).
Out of the 11 compounds profiled, BAY 11-7082 and NSC
697923 both of which contain vinyl sulphone reactive groups
(Supplementary Table 3) were found to inhibit USP7 with
moderate higher potency than other DUBs tested. For example,
BAY 11-7082 and NSC 697923 inhibited USP7 with an IC50 of
0.19 mM and 0.08 mM, respectively. The next most potently
inhibited DUB, that is, USP21, was inhibited by BAY 11-7082 and
NSC 697923 with an IC50 of 0.96 mM and 0.63 mM, respectively.
The potency of NSC 697923 for USP7 (0.08mM) was 70-fold
higher than that of HBX 41,108 (5.97 mM).
Discussion
We have developed a sensitive, reproducible and robust assay for
the analysis of DUB in vitro activity and specificity. For this, we
have made use of highly sensitive and fast MALDI-TOF mass
spectrometry, which, due to the use of 1,536-sample targets, is
suitable for robotic automation and thus high-throughput
screening53. We circumvented spot-to-spot and shot-to-shot
irreproducibility in MALDI ionization by using isotopically
labelled ubiquitin as an internal standard as it guarantees
identical extraction, crystallization and gas-phase behaviour.
Overall, this setup allowed us to achieve very high precision,
accuracy and linearity of measurements over concentrations of
almost three orders of magnitude. The advantages compared with
the commonly used assays with fluorogenic ubiquitin substrates
are the use of substrates which are more physiological and the
ability to analyse chain linkage specificity. Moreover, compared
with current techniques using SDS–PAGE, our assay is
considerably faster (2–4 h for the acquisition of 1,536 data
points) and more sensitive, thus requiring vastly reduced
amounts of diubiquitin substrate. It should be noted that the
assay is currently pipetted manually and due to addition of matrix
and trifluoroacetic acid (TFA), only 3.3% of the initial reaction
mixture is utilized for the mass spectrometry analysis. Thus, after
optimization, it should be feasible to scale down reaction amounts
at least another 20-fold using nanoliter dispensing robotics
representing a nearly 600-fold reduction in amounts of
diubiquitin needed in current low-throughput assays.
Our data has established that the MALDI-TOF DUB assay is a
powerful approach to define the substrate specificity of DUBs.
Using only 120 data points we have devised a strategy to
characterize the activity of each DUB in triplicate (that is, three
different experiments) over five concentrations spanning 10,000-
fold range against all eight diubiquitin chain linkages.
Only a few of the 42 expressed DUBs, and here particularly the
members of the UCH family, were inactive in the MALDI-TOF
DUB assay but showed high activity in the fluorogenic Ubiquitin-
Rhodamine110-Glycine assay (Table 1). This is consistent with
previous work which has shown that UCH DUBs cleave ubiquitin
moieties from protein substrates but do not hydrolyse diubiqui-
tin45,54. Interestingly, we found that members of the JAMM
family (AMSH, AMSH-LP and BRCC3) displayed high activity in
the MALDI-TOF DUB assay, exhibiting exquisite preference for
K63 linkages, but were completely inactive in the fluorescence
Ubiquitin-Rhodamine110-Glycine assay (Table 1). Therefore the
MALDI-TOF DUB assay is the preferred technology to undertake
future screening for specific inhibitors that target these
metalloproteases. Among the other inactive DUBs are ATXN3L
(MJDþ family DUB) that has been shown to preferentially
cleave ubiquitin chains with more than four units30, which is
likely to explain why no activity was observed in the MALDI-
TOF DUB and Ubiquitin-Rhodamine110-Glycine assays.
Furthermore, OTUD6B was also previously shown to be
inactive against ubiquitin dimers using a low-throughput
assay37. In our hands, full-length OTU1 expressed in
Escherichia coli (E. coli) only displayed trace activity towards
K11, K48 and K63 at the highest concentration tested
(200 ng ml 1; 3.1 mM). In another study full-length OTU1
assayed at 4mM was shown to display low activity against K11,
K27, K29, K33 and K48 (ref. 37). A different group has suggested
that OTU1 preferentially hydrolyses longer polyubiquitin
chains55, which might explain the weak activity observed55.
Further work is also required to assess whether the other enzymes
might require cofactors or posttranslational modifications, such
as phosphorylation for optimal activity as reported for OTUD5
(ref. 56). In the future, we intend to increase the coverage of the
DUB family by including more enzymes. These proteins will be
also expressed in either bacterial or insect cultures and if the
full-length protein cannot be purified, a shorter construct
encompassing the catalytic domain will be expressed.
Our data compare well to very recently published data of
DUBs of the OTU family37, confirming high specificity for many
members of this family. Also other DUB families, such as the
unspecific USPs as well as the specific JAMMs are in agreement
with the published data38,39 (Supplementary Table 2). Yet, our
data also suggests that the specificity of several DUBs depends
on the concentration of the enzymes and the enzyme/substrate
ratio. In general, highest selectivity is observed at low
concentrations of DUBs. Cezanne for example, is very
active and specific for K11 at the lowest concentration tested
(that is, 0.02 ng ml 1; B0.2 nM). Similarly, OTUD1 is very
selective for K63 at 0.2 ng ml 1 (B5 nM). However, at higher
concentrations, both Cezanne and OTUD1 lose their specificity.
These observations highlight that these enzymes are not
completely selective and possess the ability to weakly act on
other topoisomers at higher substrate concentrations. Even
several USPs, which are mostly unspecific in our assay, present
some specificity at the lowest concentrations analysed. This
emphasizes the importance that specificity of DUBs should be
tested over a wide range of enzyme concentrations, which has
not generally been undertaken in previous analyses. The
consistency of our data compared with previous work on DUB
activity and selectivity highlights the reliability of the MALDI-
TOF DUB assay technology.
None of the DUBs tested initially displayed significant activity
against K27-linked diubiquitin isomers that were purchased
commercially. We confirmed by mass spectrometry that the
commercial K27 diubiquitin molecule was indeed correctly linked
and was present in equimolar amounts compared with the other
diubiquitin isomers. We determined by pseudo-selected reaction
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Figure 3 | Inhibition profiles of 11 DUB inhibitors and inhibitor candidates. Eleven different DUB inhibitors and inhibitor candidates were pre-incubated
for 35min at two different concentrations in duplicate (that is, two different experiments) with a panel of 32 DUBs and subsequently the specific substrate
was added and incubated for 60min (30 C). Inhibition rates are colour coded with strongest inhibition in dark red, the diubiquitin topoisomers used for
each DUB are in brackets. BAY 11-7082, NSC 697923 and SJB3-019A show some selectivity at 1 mM against USP7 and USP8, respectively, while PR-619 and
HBX 41,108 inhibit strongly a wide range of DUBs even at low concentration. Other proposed inhibitors such as compound 16, L434078, WP1130 and
P22077 show low activity and selectivity in this panel.
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monitoring (pSRM) against the linkage peptides that this
diubiquitin contained small amounts (B7%) of K11 and
(B8%) K63 diubiquitin chains, which were not affecting overall
results though (Supplementary Figs 10 and 11A). In addition, we
performed circular dichroism to rule out misfolding of the isomer
(Supplementary Fig. 11B). However, to ensure that the inactivity
of all DUBs against this linkage was not due to quality issues of
the commercially produced K27 diubiquitin, we compared three
differently sourced versions of K27 diubiquitin (Boston Biochem,
UbiQ and in-house chemically engineered K27 diubiquitin57,58)
against four DUBs that had shown activity against K27 in
previous publications25,39. While USP7, USP8 and USP25 could
not hydrolyse any of the three differently sourced K27
diubiquitins in our hands, we observed that USP16 displayed
strong activity against this linkage for in-house K27 diubiquitin
but not for the commercially sourced K27-chains (Supplementary
Fig. 11C). It should be noted that previous work39 also concluded
that USP16 displayed highest activity towards K27-linked
diubiquitin isomers compared with the other DUBs tested,
suggesting that this enzyme might indeed cleave this chain type
in vitro. It is not clear why there is this discrepancy in activity of
USP16 towards in-house chemically engineered (GOPAL
methodology) and commercially available K27 diubiquitin. We
therefore re-tested the whole DUB panel against the in-house
K27 diubiquitin and except for USP16, no other DUB showed
any significant activity, agreeing with the data obtained
with commercially sourced K27 diubiquitin. This suggests that
extra caution is required when K27 diubiquitin is used for
DUB assays.
There is a huge interest in developing chemical probes that
target specific components of the ubiquitylation system59. We
have shown that the MALDI-TOF DUB assay can be readily used
to determine inhibition rates and the IC50 of small molecule
inhibitors of DUBs. The MALDI-TOF DUB assay also enables the
facile profiling of inhibitors against numerous DUBs acting on a
more physiological substrate than fluorescent ubiquitin
conjugates that have been previously employed for this
purpose28. Moreover, one will be able to employ this assay
using other physiological substrates, such as ubiquitylated
proteins. As proof of concept, we have deployed a panel of 32
active DUBs to profile 11 available DUB inhibitors and inhibitor
candidates. Our work confirms previous work that PR-619 is a
general DUB inhibitor that potently suppresses the activity of
almost all cysteine protease DUBs45. Similarly HBX 41,108,
proposed as an USP7 inhibitor48, inhibited almost all DUBs in
our assay better than USP7. Out of the compounds analysed, BAY
11-7082 and NSC 697923 displayed the highest selectivity,
inhibiting USP7 with five- to eightfold higher potency than the
second most sensitive DUB on our panel (that is, USP21). BAY
11-7082 inhibits NFkB signalling60 and was recently shown to
inhibit the majority of E2 and E3 ligases tested by reacting
covalently with the catalytic cysteine residues50. Moreover, BAY
11-7082 also inhibits several tyrosine phosphatases by reacting
with catalytic Cys residue of these enzymes61. NSC 697923 was
originally shown to inhibit the E2 ligase Ubc13-Uev1A49. These
data suggest that BAY 11-7082 and NSC 697923 are likely to
inhibit a broad range of enzymes possessing catalytic Cys
residues. Nevertheless, the moderate specificity of these
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Figure 4 | IC50 analyses of four inhibitors for selected DUBs. A subset of four inhibitors was chosen to characterize in more detail by determining their
IC50 for three DUBs. BAY 11-7082, NSC 697923 and SJB3-019A were chosen as they have some selectivity for one DUB, HBX 41,108 was chosen as it has
been proposed as a USP7 inhibitor which is an attractive drug target51. Small inhibitor compounds were pre-incubated for 35min at different concentrations
(0–30 or 0–100 mM) in triplicates (that is, three different experiments) and subsequently the specific substrate was added and incubated for 60min
(30 C). Diubiquitin topoisomers used for each DUB are named on the y axis. Data show that NSC 697923 and BAY 11-7082 inhibit strongly USP7 with
IC50o0.2mM, while HBX 41,108 inhibits it atB6mM. SJB3-019A inhibits USP8 and USP2 about 10-fold better than USP1. See also Supplementary Table 4
for P values. Error bars represent s.d. of measurements. For statistical analysis, four parameter logistic curve (best-fit solution, nonlinear regression-
dynamic fitting) and normality tests (Kolmogorov–Smirnov) are used (SigmaPlot, v. 12.5).
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compounds for USP7 indicates that it might be possible to further
engineer these compounds towards more selective probes.
Furthermore, we could show that SJB3-019A and pimozide, two
proposed USP1 inhibitors41,47, inhibit USP8 at a 10-fold lower
concentration or showed poorly selectivity, respectively. Overall
this data reveal the importance of undertaking extensive profiling
of specificity of DUB inhibitors as it is essential to ensure the
selectivity of these compounds for in vivo applications.
To screen larger numbers of small molecule inhibitors, we
propose a future screening strategy (Supplementary Fig. 7) that
can be summarized in three steps: screen 1, screening a large
number of small molecules against a single DUB to identify lead
candidates; screen 2, inhibitor specificity determination of these
lead candidates at a single concentration against a panel of a large
number of DUBs; screen 3, determination of IC50 for best DUB/
inhibitor pairs. We believe that such strategies will be useful for
discovery of specific inhibitors of DUBs which have the potential
to become important future drug targets22.
In conclusion, we present here a novel screening method to
assay DUB activity and specificity with high sensitivity,
reproducibility and reliability, which is able to carry out precise
quantified measurements at a rate of B6–9 s per sample spot.
Using physiological substrates of DUBs allowed us to determine
specificity of 42 human DUBs among which several showed high
specificity for one single-chain type. This data allowed us to
generate a simple array of preferred chain types and lowest
concentrations of activity for each DUB which will serve as a
sensitive and fast tool for screening for DUB inhibitors.
Methods
Materials. Ubiquitin monomer, BSA, Tris and DTT were purchased from Sigma-
Aldrich. Diubiquitin topoisomers (M1, K6, K11, K27, K29, K33, K48 and K63-
linked) were purchased from Boston Biochem (Boston, MA), additional K27
diubiquitin was produced in-house57,58, whereas all MALDI-TOF MS materials
(targets, matrix and protein calibration mixture) were purchased from Bruker
Daltonics (Bremen, Germany). PR-619 and P22077 (Calbiochem/Merck,
Darmstadt, Germany) as well as HBX 41,108, pimozide and degrasyn/WP1130
(Tocris Bioscience, Bristol, UK) and L434078 (Sigma-Aldrich, St Louis, MO, USA)
were purchased commercially. Febuxostat, SJB3-019A, compound 16, NSC 697923
and BAY 11-7082 were synthesized (Supplementary Table 3).
Expression of DUB enzymes. For bacterial expression, full-length or catalytic core
domains for various DUB enzymes were cloned into either pET-24, pET-28 (Nova-
gen) or pGEX6P (GE Healthcare) vectors to express either N-terminally tagged 6xHis
or GST tagged proteins. Recombinant proteins were expressed in
E. coli Bl21 (DE3) cells which were lysed by sonication lysis buffer (50mM Tris–HCl
pH 7.5, 250mM NaCl, 0.5mM EGTA, 0.5mM EDTA, 0.5% Triton X-100, 1mM
DTT, 1mM Pefabloc, 10mgml 1 Leupeptin), then centrifuged to remove insoluble
material. For protein purification, supernatants were subjected to affinity chromato-
graphy using either Ni2þ -NTA-Sepharose (GE Healthcare) or Glutathione-Sepharose
(Expedeon) resin. For insect cell protein expression, appropriate cDNAs were cloned
into the pFastBac vector, baculoviruses were generated to encode various Dac-tag-
ged62 DUB enzymes. Sf21 cells were typically infected with P1 virus stocks and
harvested 48 h later. Cells were lysed in Dac lysis buffer (40mM Tris pH 7.5, 0.2%
Triton X-100, 0.5mM EGTA, 0.1mM EDTA, 1mM DTT) supplemented with 1mM
Pefabloc and Leupeptin at 20mgml 1, then centrifuged to remove insoluble material.
For protein purification, supernatants were subjected to affinity chromatography
using ampicillin-Sepharose resin for 45min at ambient temperature. The DUB
enzymes were either eluted from the ampicillin-Sepharose by incubating 4 for
15min with 1 resin volume of 50mM Tris-HCl pH 7.5, 5% v/v glycerol, 100mM
NaCl, 10mM ampicillin, 1mM DTT, 0.03% (w/v) Brij-35 or recovered by digesting
the DUB off the Dac-tag using TEV-protease in 50mM Tris–HCl pH 7.5, 100mM
NaCl, 0.03% (w/v) Brij-35 (Supplementary Fig. 8).
15N-ubiquitin expression and purification. Untagged full-length human ubi-
quitin was cloned into the pET-24 vector and expressed in E. coli Bl21 (DE3) cells.
Cells expressing 15N-ubiquitin were grown in M9 minimal media supplemented
with 15N ISOGRO (Sigma) and Ammonium-15N chloride (Sigma) according to the
manufacturer’s instructions. Cells were sedimented, resuspended in H2O and lysed
by freeze-thawing, then centrifuged to remove insoluble material. Bacterial proteins
were precipitated by dropping the pH to 4.5 with diluted HClO4, then sedimented
by centrifugation. The supernatant containing the ubiquitin was adjusted to 20mM
ammonium-acetate pH 4.5 and applied to a Source 15 S HR10/10 column (GE
Healthcare), which was developed with a gradient of 0–1M NaCl. The 15N-ubi-
quitin eluting at a conductivity of 18mS cm 1 was concentrated and subjected to
chromatography on a Superdex75 XK16/60 column (Amersham). Final 15N-ubi-
quitin fractions were pooled and concentrated to 35mgml 1. MALDI-TOF MS
analysis revealed a 97% incorporation of 15N (Supplementary Fig. 9).
Preparation of K27-linked diubiquitin. K27-linked diubiquitin was prepared as
described57 with the following exceptions. Acceptor ubiquitin was expressed from a
new plasmid (pCDF-pylT-UbTAG27-His6) carrying an amber stop codon at
residue position 27 of ubiquitin. Crude Cbz-deprotected ubiquitin species were
then dissolved in denaturing buffer (200mM Na2HPO4 pH 7.5, 6 M guanidinium
chloride) at a final concentration of B2mgml 1. Deprotected diubiquitin was
then purified from residual monoubiquitin by semi-preparative reversed-phase
HPLC using a Dionex Ultimate 3000 system. A flow rate of 10mlmin 1 and a
gradient of 20% solvent A to 50% solvent B over 40min were used with a Thermo
Biobasic C4 (250mm 21.2mm) column (solvent A¼ 0.1% trifluoroacetic acid in
H2O; solvent B¼ 0.1% trifluoroacetic acid in acetonitrile). Fractions corresponding
to K27-linked diubiquitin were determined by liquid chromatography–MS and
were then pooled and freeze dried. Freeze dried K27-linked diubiquitin was
dissolved in denaturing buffer to a final concentration of 2mgml 1 and folded by
overnight dialysis against PBS.
In vitro DUB assays and inhibitor screening. To monitor DUB activity in vitro,
we tested a panel of 42 human DUBs at different concentrations (0.02-0.2-2-20-
200 ng ml 1) against all diubiquitin topoisomers (M1, K6, K11, K27, K29, K33, K48
and K63-linked chains) as substrates at a fixed concentration (25 ng ml 1,
1.46 mM). Both enzymes and substrates were freshly prepared in the reaction buffer
(40mM Tris–HCl, pH 7.6, 5mM DTT, 0.005% BSA) for each run. The enzymes
were pre-incubated in the reaction buffer for 10min at 30 C; afterwards, the
diubiquitin isomers were added and the reaction mixture incubated for 60min at
30 C. The reaction was stopped by adding TFA to a final concentration of 2%
(v/v). Possible background due to contamination of the diubiquitin with ubiquitin
monomers was measured in a reaction buffer in which the enzyme was excluded
and ubiquitin intensities normalized accordingly (Supplementary Fig. 10B-2).
Dimer purity was controlled by SDS–PAGE, PRM and MALDI-TOF MS/MS
(Supplementary Figs 10 and 11).
For the small molecule inhibitor studies, we tested the MALDI-TOF DUB
methodology by screening 11 DUB inhibitors or inhibitor candidates. To assess
linearity for inhibitor experiments, time-dependent inhibition experiments were
performed by adding increasing concentrations of the compound, from 0 to 90 mM,
to the reaction buffer containing USP7 (1 ng ml 1) and incubated for 30min at
30 C. We demonstrated the linearity of response of USP7 (1 ng ml 1) versus K11-
linked diubiquitin (1.46 mM) to increasing concentrations of PR-619 (0–40 mM)
over time (0–20min) (Supplementary Fig. 6). Some of these inhibitors could
potentially react with reducing agents present in the assay such as dithiothreitol
(DTT) or tris(2-carboxyethyl) phosphine (TCEP). We therefore verified using
MALDI-TOF mass spectrometry whether the inhibitor compounds reacted with
either 1mM DTT or 0.5mM TCEP when incubated at 30 C for 1 h under the DUB
assay conditions employed. This revealed that only WP1130 significantly reacted
with both DTT and TCEP under these conditions (data not shown). For all
inhibitor experiments, except PR-619 and HBX 41,108, no DTT but the remaining
trace levels from the protein expression was added to the reaction buffer.
Following the scheme in Supplementary Fig. 7, we determined the activity of
the inhibitors in two steps. First of all, we screened the inhibitors in duplicates
against 32 DUBs. The enzymes were pre-incubated with either 1 or 3/5/10 mM of
inhibitor for 35min at 30 C. Next, substrates were incubated with the enzyme
plus inhibitor mixture for 60min at 30 C. Second, we determined the inhibitors’
IC50 on a subset of selected DUBs. For calculation of IC50, data were fitted in
SigmaPlot (v. 12.5 Build 12.5.0.38) using the four parameter logistic equation:
y¼minþ (maxmin)/(x/IC50) Hillslope. Values of IC50 for all compounds are
summarized in Supplementary Table 4.
Analysis by MALDI-TOF MS. Sample preparation. Acidified samples of the DUB
assays were mixed with 0.5 mM 15N-ubiquitin and then with one part of 2% (v/v)
TFA and one part of 2,5 DHAP matrix solution (7.6mg of 2,5 DHAP in 375 ml
ethanol and 125 ml of an aqueous 12mgml 1 diammonium hydrogen citrate).
Then 0.5 ml of these solutions were spotted in replicates onto an MTP AnchorChip
1,536 TF (600 mm anchor, Bruker Daltonics).
Data acquisition. A high resolution MALDI-TOF MS instrument
(UltrafleXtreme, Bruker Daltonics) with Compass 1.3 control and processing
software was used. Samples were run in automatic mode (AutoXecute, Bruker
Daltonics) allowing 6–9 seconds per spot, using the 1,536 spots AnchorChip.
Ionization was achieved by a 1-kHz smartbeam-II solid state laser with a fixed
initial laser power of 60% (laser attenuator offset 68%, range 30%) and detected by
the FlashDetector at detector gain of  10. Reflector mode was used with
optimized voltages for reflector-1 (26.61 kV) and reflector-2 (13.39 kV), ion sources
(IonSource-1: 24.86 kV, IonSource-2: 22.71 kV) and pulsed ion extraction (320 ns).
Sampling rate was 0.25 ns equivalent to a 4 GS/s digitization rate. An amount of
2,100 (3 700) shots were summed up in ‘random walk’ and with ‘large’
smartbeam laser focus. Spectra were accumulated by FlexControl software (v. 3.3
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Build 108), processed using FlexAnalysis software (v. 3.3, Build 80) and the
sophisticated numerical annotation procedure (‘SNAP’) peak detection algorithm,
setting the signal-to-noise threshold at 250. Before calibration, the spectra were
processed using smoothing (Savitzky–Golay algorithm) and baseline subtraction
(‘TopHat’) for reproducible peak annotation on nonresolved isotope distributions:
one cycle, 0.2 m/z for the width. For external interactive calibration in quadratic
mode, the ‘Protein Calibration Standard 1’ (Bruker) was used with ubiquitin
([MþH]þ average¼ 8,565.76), myoglobin ([Mþ 2H]2þ average¼ 8,476.66) and
cytochrome c ([Mþ 2H]2þ average¼ 6,181.05, [MþH]þ ¼ 12,360.97) ions as
average m/z values. Internal calibration was performed using the ubiquitin peak
([MþH]þ average¼ 8,565.76). An example of a full scan MALDI spectrum is
depicted in Supplementary Fig. 12.
Data analysis. A modified method for data acquisition was developed for
FlexAnalysis Software, using the SNAP algorithm. This algorithm is calculating an
isotopic distribution which best fits the pattern of an isotopically resolved protein
signal. For area calculation, the complete isotopic distribution was taken into
account. Data output was exported as a.csv file using FlexAnalysis Batch Process
(Compass 1.3) and further processed in Microsoft Excel, where plotting of graphs,
calculation of s.d. and coefficient of variation (%) were performed. The
measurement of DUB activity (% of diubiquitin isomer consumed, x) from relative
isotopic distribution summed area ratios was performed according to equation (1),
x¼ AreaUbi
Area 15NUbi
 15NUbi 
 
2
 
= DiUbi½ 100 : ð1Þ
Quality control of diubiquitin isomers by MALDI-TOF and PRM. Two micro-
grams of each diubiquitin chain was resolved by SDS–PAGE (4–20%, Tris-Glycine,
Novex, Life Technologies), stained by InstantBlue Coomassie stain (Expedeon).
Bands were excised and digested with trypsin (Supplementary Fig. 10A). Gel pieces
were washed subsequently with water, 50% methanol/water, 0.1M NH4HCO3, then
shrunk in acetonitrile and digested with trypsin (Pierce). The digestion was per-
formed overnight at 37 C and peptides were extracted further in 50% acetonitrile/
2.5% TFA. Digests were dried and reconstituted in 0.1% TFA/water to 15 mgml 1.
A total of 30 ng of each digest was injected onto a 15 cm 75mm (I.D.) EasySpray
column (Thermo Fisher Scientific) and analysed on an LTQ-Velos Pro ion trap
(Thermo Fisher Scientific) using a PRM63 specific for each diubiquitin chain
linkage (Gly-Gly) peptide (Supplementary Figs 10C and 11A). Lists of precursor
masses and fragment transitions are reported in Supplementary Table 5. Data were
acquired in a data-independent mode with one full scan followed by 10 MS2 scans
with the masses of the different linkages. MS2 occurred even if precursor mass was
not detected in MS1 scan. Extracted ion chromatograms of the MS2 spectra for each
diubiquitin chain peptide was performed by summing the ion current of the three
or four most dominant daughter ions.
The linkage peptide of K29-diubiquitin does not bind to the trap column
(Acclaim PepMap100 C18, 5 mm, Thermo Fisher Scientific) of the liquid
chromatography–MS system under normal conditions. We therefore analysed the
purity of this diubiquitin by MALDI-TOF MS (Supplementary Fig. 10D). Fifteen
nanograms per microlitre of digested diubiquitin was mixed with 10mgml 1
alpha-cyano-4-hydroxycinnamic acid (1:1) and spotted onto a 384 AnchorChip
target (Bruker Daltonics). For MS2, LIFT technology was performed and the data
were processed by Mascot server through BioTools (Bruker Daltonics).
Ubiquitin-Rhodamine110-Glycine expression, purification and preparation.
For the cloning of the ubiquitin-intein-His6 expression vector, the coding region for
amino acids 1–75 of human ubiquitin were amplified by PCR with suitable primers for
subsequent cloning into intein expression vector pTYB2 as described28. Ubiquitin-intein-
His6 was expressed and purified as described28 with the following exceptions. Ubiquitin-
intein was batch purified on nickel chelating affinity media (Amersham) and Ubiquitin-
MES was released by addition of 100mM Na-mercaptoethanesulfonate (MES) for 5h at
22 C. Ubiquitin-MES was eluted with 4 column volumes of 20mM 2-(N-morpholino)
ethanesulfonic acid, pH 6.5, 100mM NaCl. Eluted material was concentrated by
ultrafiltration (Vivaspin 6, 5-kDa cutoff) to o5ml and supplemented with 10 eq. N-
hydroxysuccinimide (Fluka 56480), 10 eq. sym-collidine (Fluka 27690) and 15 eq. bis-
glycyl-rhodamine110 (prepared in-house) for 24h at 37 C. For purification the reaction
mixture was desalted into 20 mM 2-(N-morpholino) ethanesulfonic acid, pH 6.5 on a
HiPrep Sephadex G-25 26/10 column (GE healthcare) then applied to a Source 15 S HR
10/10 column (GE healthcare) which was developed with a gradient of 0–1 NaCl. Final
Ubiquitin-Rhodamine110-Gly fractions were pooled, dialysed into 50mM Tris, pH 7.5
then concentrated to 1mgml 1. In the fluorescent assay, 0.5mM Ubiquitin-
Rhodamine110-Gly in 40mM Tris-HCl buffer, pH 7.6, 5mM DTT and 0.05 mg ml-1
BSA were incubated with 0.05–5ngml 1 of each DUB for 60min at 30C. Samples were
prepared in triplicates and analyzed in 96-well plates using a Perkin Elmer Envision 2104
multi label reader at Excitation/Emission 485/535nm (ref. 28).
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